{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:03:09Z","timestamp":1778803389726,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.canep.2025.102769","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T08:43:00Z","timestamp":1739349780000},"page":"102769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Treatment switching between Enzalutamide and Abiraterone Acetate and time to oral opioid initiation in castration-resistant prostate cancer patients"],"prefix":"10.1016","volume":"95","author":[{"given":"Ibrahim M.","family":"Asiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viraj","family":"Master","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanyu","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folakemi T.","family":"Odedina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H.","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon C.","family":"Tilburt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irbaz B.","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Arsalan Ahmed","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-7761","authenticated-orcid":false,"given":"Steven R.H.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-312X","authenticated-orcid":false,"given":"Ewan K.","family":"Cobran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.canep.2025.102769_bib1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","article-title":"NCCN guidelines\u00ae insights: prostate cancer early detection, version 1.2023","volume":"21","author":"Moses","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"6","key":"10.1016\/j.canep.2025.102769_bib2","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/JOP.2014.001701","article-title":"Systemic therapy in men with metastatic castration-resistant prostate cancer: American society of clinical oncology and cancer care Ontario clinical practice guideline summary","volume":"10","author":"Basch","year":"2014","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.canep.2025.102769_bib3","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae)","volume":"2018","author":"Network","year":"2018","journal-title":"Prostate Cancer"},{"issue":"8","key":"10.1016\/j.canep.2025.102769_bib4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1634\/theoncologist.2015-0166","article-title":"U.S. food and drug administration approval summary: enzalutamide for the treatment of patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer","volume":"20","author":"Ning","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.canep.2025.102769_bib5","doi-asserted-by":"crossref","first-page":"14131","DOI":"10.1038\/s41598-021-93659-x","article-title":"Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer","volume":"11","author":"Demirci","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.canep.2025.102769_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.canep.2025.102769_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2010.136","article-title":"Drug resistance in metastatic castration-resistant prostate cancer","volume":"8","author":"Seruga","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canep.2025.102769_bib8","series-title":"Urologic Oncology: Seminars and Original Investigations","article-title":"Navigating the evolving therapeutic landscape in advanced prostate cancer","author":"Crawford","year":"2017"},{"issue":"8","key":"10.1016\/j.canep.2025.102769_bib9","first-page":"IV-3","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med. Care"},{"key":"10.1016\/j.canep.2025.102769_bib10","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Overview Fact Sheets, NCI, Rockville, MD, Cited February 16, 2024. Available from: \u3008https:\/\/seer.cancer.gov\/about\/factsheets\/SEER_Overview.pdf\u3009."},{"issue":"1","key":"10.1016\/j.canep.2025.102769_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","article-title":"The incident user design in comparative effectiveness research","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.canep.2025.102769_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr. Epidemiol. Rep."},{"issue":"7","key":"10.1016\/j.canep.2025.102769_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9","key":"10.1016\/j.canep.2025.102769_bib14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am. J. Epidemiol."},{"issue":"5S","key":"10.1016\/j.canep.2025.102769_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.6004\/jnccn.2018.0036","article-title":"NCCN guidelines updates: prostate cancer and prostate cancer early detection","volume":"16","author":"Carroll","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"2","key":"10.1016\/j.canep.2025.102769_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.juro.2014.10.104","article-title":"Castration-resistant prostate cancer: AUA guideline amendment","volume":"193","author":"Cookson","year":"2015","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.canep.2025.102769_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2013 United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm. Rep."},{"issue":"6","key":"10.1016\/j.canep.2025.102769_bib18","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/j.1475-6773.2006.00585.x","article-title":"Colorectal cancer screening in the elderly population: disparities by dual Medicare-Medicaid enrollment status","volume":"41","author":"Koroukian","year":"2006","journal-title":"Health Serv. Res."},{"issue":"4","key":"10.1016\/j.canep.2025.102769_bib19","first-page":"57","article-title":"Disabled Medicare beneficiaries by dual eligible status: California, 1996\u20132001","volume":"28","author":"O'Leary","year":"2007","journal-title":"Health Care Financ Rev."},{"issue":"1","key":"10.1016\/j.canep.2025.102769_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1475-6773.2009.01051.x","article-title":"The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study","volume":"45","author":"Koroukian","year":"2010","journal-title":"Health Serv. Res."},{"issue":"13","key":"10.1016\/j.canep.2025.102769_bib21","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/cncr.27975","article-title":"Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study","volume":"119","author":"Stokes","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.canep.2025.102769_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"6","key":"10.1016\/j.canep.2025.102769_bib23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs","volume":"275","author":"St\u00fcrmer","year":"2014","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.canep.2025.102769_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.canep.2025.102769_bib25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.canep.2025.102769_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2025.102769_bib27","first-page":"1","article-title":"Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate","author":"Tagawa","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"10","key":"10.1016\/j.canep.2025.102769_bib28","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s12325-018-0774-1","article-title":"Treatment duration, healthcare resource utilization, and costs among chemotherapy-naive patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: a retrospective claims analysis","volume":"35","author":"Schultz","year":"2018","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.canep.2025.102769_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/aje\/kwaa190","article-title":"Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014\u20132018 French population study (the SPEAR cohort)","volume":"190","author":"Scailteux","year":"2021","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.canep.2025.102769_bib30","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/cam4.3810","article-title":"Opioid use by cancer status and time since diagnosis among older adults enrolled in the prostate, lung, colorectal, and ovarian screening trial in the United States","volume":"10","author":"Durham","year":"2021","journal-title":"Cancer Med."},{"issue":"49","key":"10.1016\/j.canep.2025.102769_bib31","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.canep.2025.102769_bib32","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s00345-018-2416-2","article-title":"Imaging modalities in synchronous oligometastatic prostate cancer","volume":"37","author":"Futterer","year":"2019","journal-title":"World J. Urol."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782125000281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782125000281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T19:32:46Z","timestamp":1759001566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782125000281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"alternative-id":["S1877782125000281"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2025.102769","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment switching between Enzalutamide and Abiraterone Acetate and time to oral opioid initiation in castration-resistant prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2025.102769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102769"}}